|
|
|
| Overexpression of regulatory factor X5 in digestive system neoplasm |
| ZHAO Yang-jing1,2, XIE Xing-wang2, ZHANG Henghui2, CAO Hui3, WEI Lai2, CHEN Hong-song2, SHAO Qi-xiang1 |
| （1. School of Medicine, Jiangsu University, Zhenjiang Jiangsu 212013; 2. Beijing Key Laboratory of Hepatitis C and Immunotherapy for Liver Disease, Peking University Hepatology Institute, Peking University People′s Hospital, Beijing 100044; 3. Department of Pathology, the First Affiliated Hospital of Zhejiang University, Hangzhou Zhejiang 310003, China) |
|
|
|
|
Abstract [Abstract]Objective: To investigate the expression levels of regulatory factor X5(RFX5) in digestive system neoplasms. Methods: RFX5 mRNA expression levels were determined by analyzing the RNAseq data from the the Cancer Genome Atlas(TCGA) database. By using tissue microarray technology and immunohistochemical staining, RFX5 protein expression was confirmed in six different types of digestive system tumors(esophageal, stomach, colon, rectal, liver and pancreatic cancers) and corresponding nontumor normal tissues. Results: RFX5 mRNA and protein levels were upregulated in six malignancies, and the altitudes increase more significantly in stomach adenocarcinoma and hepatocellular carcinoma than other cancer types. Conclusion: Expressions of RFX5 mRNA and protein were both elevated in digestive system neoplasms.
|
|
Received: 11 January 2016
|
|
|
|
| [1\]Aftab S, Semenec L, Chu JS, et al. Identification and characterization of novel human tissuespecific RFX transcription factors\[J\]. BMC Evol Biol, 2008,8:226.\[2\]Villard J, Reith W, Barras E, et al. Analysis of mutations and chromosomal localisation of the gene encoding RFX5, a novel transcription factor affected in major histocompatibility complex class Ⅱ deficiency\[J\]. Hum Mutat,1997,10(6):430-435.\[3\]Zhou X, Zhu HQ, Lu J. Regulation of gene expression in HBV and HCVrelated hepatocellular carcinoma: Integrated GWRS and GWGS analyses\[J\]. Int J Clin Exp Med,2014,7(11):4038-4050.\[4\]Michel S, Linnebacher M, Alcaniz J, et al. Lack of HLA class Ⅱ antigen expression in microsatellite unstable colorectal carcinomas is caused by mutations in HLA class Ⅱ regulatory genes\[J\]. Int J Cancer, 2010,127(4):889-898.\[5\]Han CP, Lee MY, Tzeng SL, et al. Nuclear Receptor Interaction Protein (NRIP) expression assay using human tissue microarray and immunohistochemistry technology confirming nuclear localization\[J\]. J Exp Clin Cancer Res,2008,27:25.\[6\]Xie XW, Mei MH, Liao WJ, et al. Expression of CIITArelated MHCⅡ molecules in tumors linked to prognosis in hepatocellular carcinoma\[J\]. Int J Oncol,2009,34(3):681-688.\[7\]Paterson AC, Sciot R, Kew MC, et al. HLA expression in human hepatocellular carcinoma\[J\]. Br J Cancer,1988, 57(4):369-373.\[8\]Marquardt JU, Thorgeirsson SS. SnapShot: Hepatocellular carcinoma\[J\]. Cancer Cell,2014,25(4):550.\[9\]Kloor M, Michel S, von Knebel DM. Immune evasion of microsatellite unstable colorectal cancers\[J\]. Int J Cancer,2010,127(5):1001-1010.\[10\]Surmann EM, Voigt AY, Michel S, et al. Association of high CD4positive T cell infiltration with mutations in HLA class Ⅱregulatory genes in microsatelliteunstable colorectal cancer\[J\]. Cancer Immunol Immunother, 2015, 64(3):357-366.\[11\]Ji X, Li J, Zhu L, et al. CHD1L promotes tumor progression and predicts survival in colorectal carcinoma\[J\]. Cardiothoracic,2013,185(1):84-91.\[12\]Wang K, Lim HY, Shi S, et al. Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma\[J\]. Hepatology,2013,58(2):706-717.\[13\]Mani M, Carrasco DE, Zhang Y, et al. BCL9 promotes tumor progression by conferring enhanced proliferative, metastatic, and angiogenic properties to cancer cells\[J\]. Cancer Res, 2009, 69(19): 7577-7586 |
|
|
|
2016, Vol. 26 
